7月13日 - ** 制药公司MBX Biosciences（MBX.O）的股价在盘后交易中下跌2.6%，至58.49美元
** MBX任命内部人士史蒂夫·霍尔特（Steve Hoerter）为新任首席执行官，接替肯特·霍里卢克（Kent Hawryluk）
** 任命自2026年3月起担任临时首席财务官的约翰·斯米瑟（John Smither）为新任首席财务官
** 所有管理层变动即刻生效
** 今年迄今，MBX股价已翻近一倍
7月13日 - ** 制药公司MBX Biosciences（MBX.O）的股价在盘后交易中下跌2.6%，至58.49美元
** MBX任命内部人士史蒂夫·霍尔特（Steve Hoerter）为新任首席执行官，接替肯特·霍里卢克（Kent Hawryluk）
** 任命自2026年3月起担任临时首席财务官的约翰·斯米瑟（John Smither）为新任首席财务官
** 所有管理层变动即刻生效
** 今年迄今，MBX股价已翻近一倍
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.